Bris­tol My­ers adds to neoad­ju­vant win for Op­di­vo in lung can­cer, es­ca­lat­ing ear­ly can­cer show­down with Mer­ck

Bris­tol My­ers Squibb and Mer­ck are locked in a heat­ed race to bring their block­buster PD-(L)1 drugs in­to ear­ly can­cer pa­tients as part of po­ten­tial­ly cu­ra­tive com­bi­na­tions. The ap­provals have been com­ing fast and heavy, and Bris­tol My­ers keeps adding to its case for a big-time FDA nod in lung can­cer.

A com­bi­na­tion of Op­di­vo and chemo in the neoad­ju­vant set­ting be­fore surgery cut the risk of re­cur­rence or death in pa­tients with stage IB to II­IA non-small cell lung can­cer over pre-surgery chemo alone, ac­ing the sec­ond pri­ma­ry end­point in the Phase III CHECK­MATE-816 study, Bris­tol My­ers said Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER